KYMRIAH

This brand name is authorized in Austria, Canada, Croatia, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug KYMRIAH contains one active pharmaceutical ingredient (API):

1	Tisagenlecleucel UNII Q6C9WHR03O - TISAGENLECLEUCEL
	Tisagenlecleucel is an autologous, immunocellular cancer therapy which involves reprogramming a patient’s own T cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19 expressing cells.
	Read more about Tisagenlecleucel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KYMRIAH Dispersion for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01X	Other antineoplastic agents	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents
Discover more medicines within L01X
L01XL04		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XL Antineoplastic cell and gene therapy
Discover more medicines within L01XL04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02480514
EE	Ravimiamet	1778430
ES	Centro de información online de medicamentos de la AEMPS	1181297001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	565299
FR	Base de données publique des médicaments	65647882
GB	Medicines & Healthcare Products Regulatory Agency	381076
HK	Department of Health Drug Office	66588
IL	מִשְׂרַד הַבְּרִיאוּת	8481
IT	Agenzia del Farmaco	046996017
LT	Valstybinė vaistų kontrolės tarnyba	1086209
PL	Rejestru Produktów Leczniczych	100410189
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65093001